Navigation Links
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Date:9/25/2008

Data Validates Neuroprotective Effect of Quark's New RNAi Product on Dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma

FREMONT, Calif., Sept. 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced QPI-1007 as the Company's first siRNA drug candidate based on its own intellectual property for a host of novel structures having freedom to operate in the siRNA IP space. QPI-1007, which is currently being evaluated in advanced IND enabling preclinical studies as a neuroprotective agent for eye diseases, is the first drug candidate to utilize a novel siRNA structure developed by Quark free of third party IP. The Company is utilizing its proprietary structures and intellectual property to develop additional RNAi drug candidates in its robust pipeline.

Quark has completed studies with QPI-1007 in different animal models of acute and severe optic nerve injury. In collaboration with Prof. Ann Logan of the Division of Medical Sciences, Department of Medicine, University of Birmingham, UK, Quark examined QPI-1007's effectiveness in a model of retinal ganglion cell (RGC) death by optic nerve crush (ONC). In a second study of QPI-1007 in collaboration with Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal, its effectiveness was examined in a model of RGC death induced by axotomy of the optic nerve. QPI-1007 displayed neuroprotective activity towards RGCs. It significantly protected retinal neurons against delayed degeneration and reduced injury induced RGC death in vivo, the hallmarks of glaucoma and acute injuries such as ischemic optic neuropathy.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "With more RNAi products in human trials than any other company in the industry, Quark has proven its ability to advance siRNA products from discovery to the clinic.
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 This report analyzes the worldwide markets ... following Product Segments: SPECT Systems (Includes SPECT and SPECT/CT systems), ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2013 through 2020. Also, ...
(Date:9/16/2014)... 2014 3SBio Inc., ("3SBio") a leading ... focusing on researching, developing, manufacturing and marketing ... into an exclusive license agreement with JenKem Technology ... marketing in Mainland China of PEG-irinotecan, a long-acting ... is over-expressed in many solid tumors, including colorectal, ...
(Date:9/16/2014)... The Pulmonary Fibrosis Foundation (PFF) announced today ... 1,100 patients and families suffering from pulmonary fibrosis (PF) ... the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis ... to seek patient input in order to better understand ... "We applaud the FDA for focusing its attention on ...
Breaking Medicine Technology:Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 263SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical applications, has entered into a new, ... SANTE (SES) of Algiers, Algeria for the distribution ...
... BME (BioMedical Enterprises, Inc.), a developer and manufacturer ... United States launch of Speed™. It is the first ... to orthopaedic and podiatric surgeons. BME, the ... its extensive knowledge in memory metal implant design to ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Algeria 2Misonix Announces New Distribution Agreement for Algeria 3
(Date:9/16/2014)... Keep that sexy decolletage as you age, and frame ... Face Whisperer Neck & Decollete Cream is made ... Sublime Beauty®. "It contains rich ingredients to care for the ... A special ingredient is Argireline, known as the natural botox, ... comes in an airless pump bottle, and is part of ...
(Date:9/16/2014)... Park City, UT (PRWEB) September 16, 2014 ... Health Benefits Solution, published new information on transitioning ... to Zane Benefits, with the Affordable Care Act ... sized businesses will be steering some or all ... comes as no surprise. With guaranteed issue plans, ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 UWDress.com, the ... new elegant evening wear assortment online. Additionally, ... products. All people can access big discounts now, up ... company’s elegant evening gowns are charming; it has won ... Along with evening outfits, it is also providing big ...
(Date:9/16/2014)... a healthcare climate where the costs of treatment ... study has found that radiation oncologists are using ... with early-stage breast cancer. The findings are scheduled ... of the American Society for Radiation Oncology in ... Radiotherapy for Elderly Women: Response to a Randomized ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous dress ... shoulder evening gown collection. According to the company’s sales ... rates (up to 69% off) at present. Additionally, all the ... “I am a frequent caller of your site. I like ... I feel quite happy. All items are of good quality. ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2
... 27 Aflac Incorporated,(NYSE: AFL ) announced today ... & Woods 2008 Insurance Conference. President and Chief Financial,Officer ... is,scheduled to make a presentation on September 3, 2008, ... Cloninger will discuss the,company,s outlook for the remainder of ...
... wages and benefits, HEMET, Calif., Aug. 27 The ... against the,board of directors of Valley Health System (VHS) for ... already voted to agree to., "I do this job ... said,Lisa Howell, a registered nurse at Menifee Valley Medical Center. ...
... HARRISBURG, Pa., Aug. 27 Believe it or not,women ... women,s oral,health needs change at different stages throughout their ... Association (PDA) offers a reminder that,understanding these evolving oral ... stage of life, is getting the oral health care ...
... help regain pre-pregnancy body, IRVINE, Calif., ... of post-baby body shaping solution VelaShape(TM),and other ... body,contouring, today reveals the results of the ... women,s desire to regain their,pre-pregnancy body. Syneron ...
... not all part of normal aging process , , WEDNESDAY, Aug. ... women who remain free of dementia will nonetheless undergo an ... years before their death, a new study reveals. , Verbal ... of this cognitive decline, which is not, the researchers stressed, ...
... women quit smoking during pregnancy to protect their unborn children from ... a few months of giving birth. , By shedding light ... that cigarette for good, a study by researchers at the University ... to help women quit and stay quit. , According to the ...
Cached Medicine News:Health News:Aflac Incorporated To Present at the Keefe, Bruyette & Woods 2008 Insurance Conference 2Health News:State Board Issues Complaint: VHS Board Should Have Signed Contract With Caregivers 2Health News:What You Need to Know About Women's Oral Health 2Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 2Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 3Health News:Celebrity Moms' Post-Baby Body Triggers Jealousy, Skepticism in U.S. Moms 4Health News:Mental Skills Can Decline Years Before Dying 2Health News:Mental Skills Can Decline Years Before Dying 3Health News:Newly-defined factors may prevent postpartum smoking relapse 2Health News:Newly-defined factors may prevent postpartum smoking relapse 3
Used in the peritoneal cavity to remove large volumes of thick exudate....
100cc silicone evacuator...
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Medicine Products: